Table 3.
Comparison with different treatments studies for EGFR mutant LA-NSCLC.
| Study | Type | Center | No. of patients |
Treatment | mFU (months) | ORR | mPFS (months) | MST (months) |
Pneumonitis incidence |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| G2 | G3-G4 | G5 | |||||||||
| CRT | |||||||||||
| Kosuke Tanaka, et al. (2015)5 | R | S | 29 | CCRT | 35 | 74% | 9.8 | 51.1 | NA | NA | NA |
| Yu Jin Lim, et al. (2017)6 | R | S | 26 | CCRT | 22.4 | 89% | NA | 3 years: 68% | NA | NA | NA |
| Song Ee Park, et al. (2019)7 | R | S | 36 | CCRT | 66.5 | 72.2% | 8.9 | 34.6 | NA | NA | NA |
| Masaki Nakamura, et al. (2019)8 | R | S | 34 | CCRT/SCRT | 36.0 | NA | 3 years: 15% | 3 years: 46% | NA | NA | NA |
| Shigehiro Yagishita, et al. (2014)9 | R | S | 34 | CCRT/SCRT | 29.0 | 79% | NA | 46.9 | NA | NA | NA |
| Hiroaki Akamatsu, et al. (2014)10 | R | S | 13 | CCRT | NA | 76.9% | 9.6 | 57.9 | NA | NA | NA |
| HIDETOSHI HAYASHI, et al. (2012)11 | R | S | 11 | CCRT/SCRT | 20.7 | 90.9% | 13.1 | 67.5 | NA | NA | NA |
| Hidehito Horinouchi, et al. (2020)12 | R | M | 29 | CCRT/SCRT | 31.6 | NA | 16.9 | NA | NA | NA | NA |
| Jacqueline V. Aredo, et al. (2021)20 | R | M | 16 | CCRT | 14.5 | NA | 6.9 | NA | 8.3% | 16.7% | 0 |
| Our Study | R | M | 104 | CCRT/SCRT | 49.3 | NA | 12.4 | 51.0 | NA | NA | 0 |
| CRT/RT+TKI | |||||||||||
| LOGIK0902/OLCSG0905 (2021)32 | P | M | 20 | TKI +CCRT | 47.5 | 75% | 2 years: 37% | 2 years: 90% | NA | 0 | 0 |
| RECEL (2021)26 | P | M | 20 | RT+TKI | 21.3 | 70% | 24.5 | NA | NA | 16.7% | 0 |
| WJOG6911L (2021)27 | P | M | 28 | RT+TKI | 51.8 | 81.5% | 18.6 | 61.1 | 30% | 4% | 0 |
| Jacqueline V Aredo, et al. (2021)20 | R | M | 8 | CRT+TKI | 14.5 | NA | 26.1 | NR | NA | NA | NA |
| Our Study | R | M | 105 | CRT/RT+TKI | 38.1 | NA | 26.2 | 67.4 | NA | NA | 0 |
| TKI alone | |||||||||||
| Ranpu Wu, et al. (2021)33 | R | S | 63 | TKI | NA | NA | 13.87 | 41.47 | NA | NA | NA |
| Our Study | R | M | 231 | TKI | 30.7 | NA | 16.2 | 49.3 | NA | NA | 0 |
Abbreviations: CCRT, concurrent chemoradiotherapy; CRT, chemoradiation therapy; EGFR, epidermal growth factor receptor; LA-NSCLC, locally advanced non-small cell lung cancer; M, multi-center; mFU, median follow-up time; mPFS, median progression-free survival; MST, median overall survival time; NA, not available; ORR, objective response rate; P, perspective; R, retrospective; RT, radiation therapy; S, single center; SCRT, sequential chemoradiotherapy; TKI, Tyrosine kinase inhibitor.